The 6th edition of the Phage Therapy Congress world conference on Targeting Phage Therapy is an in-person and online event, which will be held in Paris, France from Thursday 1st June till Friday 2nd June 2023.
What is the 6th Targeting Phage Therapy conference and Why attend?
Questions, Controversies, and What is Next? Strategies to bring phage therapy to another level
Targeting Phage Therapy 2023 will highlight the recent innovations and clinical applications of phages, validation and limitations. Targeting Phage Therapy 2023 will also cover how phages will transform the medicine of tomorrow. Phages will be the hottest topic not only to combat infection and antibiotic resistance, but also to modulate microbiota.
Who will be at the 6th Targeting Phage Therapy conference?
Over 20 speakers and key global leaders from across the globe will be attending.
A discussion will be held on how to overcome barriers between experts, academics, industrials, and regulators.
Agenda for the 6th Targeting Phage Therapy 2023
Thursday 1st June 2023
Domenico Frezza from University of Roma Tor Vergata, Italy, and Marvin Edeas from INSERM – Institut Cochin, Université de Paris, France – General Introduction of Targeting Phage Therapy 2023
Martha Clokie from University of Leicester, United Kingdom – Challenges and Opportunities for Bacteriophage Therapy
Domenico Frezza from University of Roma Tor Vergata, Italy – Phage Therapy: Vision, Gaps and Evolution
Mzia Kutateladze from Eliava Institute of Bacteriophage, Georgia – Bacteriophage Therapy: From Soviet Clinical Experience to Current Activities at the Eliava Institute
William Summers from Yale University, USA – Historical Reflections of the Trials and Tribulations of Phage Therapy: 1930-1950
Jean-Paul Pirnay from Queen Astrid Military Hospital, Belgium – Bacteriophages: It’s a medicine, Jim, but not as we know it
Lilian Musila from U.S. Army Medical Research Directorate, Kenya – Potential of Therapeutic Phages to Combat MDR ESKAPE Pathogens in Developing Nations
Jessica Sacher from Co-Founder of Phage Directory, Australia – Scaling Phage Therapy, Starting with Phage Australia
Ryszard Międzybrodzki from Hirszfeld Institute of Immunology and Experimental Therapy PAS, Poland – Phages in the Medical Research Activity in Poland
Pranav Johri from Founder of Vitalis Phage Therapy, India – From Patient to Advocate – Introducing Phage Therapy to India
Tristan Ferry from Hospices Civils de Lyon, France – The Use of Bacteriophage Therapy for Complex Bacterial Infections: the PHAGEinLYON Experience
Jolien Onsea from KU Leuven, Belgium – The Use of Bacteriophage Therapy for Difficult-to-Treat Musculoskeletal Infections: the PHAGEFORCE Experience
Cara Fiore from Food and Drug Administration (FDA), USA – The Regulation of phage therapy applications in humans in the USA
Marvin Edeas Chairman of The Scientific Committee, Université de Paris, INSERM 1016, Institute Cochin, France – Introduction to Bacteriophages & Microbiota: On the Way to a Medical Revolution?
Martial Marbouty from Institut Pasteur, France – Phage-Bacteria Interaction Network in Human Intestinal Tract
Ben Raymond from University of Exeter, United Kingdom – Phage & Microbiota Modulation: Synergetic Role of Phage and Probiotics
Maryoris Elisa Soto Lopez from Universidad De Córdoba, Colombia – First Report of Bacteriophages for Biocontrol of Escherichia Coli at the North Colombian Coast in Typical Caribbean Cheese (Queso Costeño)
Sophia Baldysz from Adam Mickiewicz University Poznań, Poland – Crack the Wall from Side to Side – Phage Lytic Proteins as Potential Antimicrobials
Raquel De Souza Praia from Escola Superior de Tecnologia, Brazil – Proposal for Therapy with Bacteriophages in Former Military Fire Fighters
Ekaterina Chernevskaya from the Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Russia – Phage Therapy in Post-Covid Rehabilitation
Dmitry Pushkar from Yevdokimov Moscow State University of Medicine and Dentistry, Russia – Results of a Study of a Drug for Intravesical Administration Based on Bacteriophages in Patients with Chronic Recurrent Cystitis
Friday 2nd June 2023
Mariagrazia Di Luca from University of Pisa, Italy – Phage-based drugs for the treatment of biofilm-associated infections
Farzaneh Moghtader from SET Medikal/NanoBMT, Turkey – Combined Therapies of Wound Infections with Phages/MSCs Aggregates
Anna Pistocchi from Università degli Studi di Milano, Italy – Investigating the Therapeutic Potential of Phages as Antibacterials and Immunomodulators in a Zebrafish Model of Cystic Fibrosis
Mina Pastagia from Armata Therapeutics, USA – Safety, Pharmacokinetics, and Antibacterial Activity of AP-PA02 Multi-phage Cocktail in Patients with Cystic Fibrosis and Chronic Pulmonary Pseudomonas aeruginosa Infection (SWARM-P.a. Clinical Trial)
Alexander Sulakvelidze President and CEO of Intralytix, Inc., USA – Modern Approaches for Optimizing Therapeutic Phage Preparations
Aleksandra Petrovic Fabijan from Westmead Institute for Medical Research, Australia – Therapeutic Monitoring of Phage Therapy
Anthony Maresso from TailΦr Labs, Baylor College of Medicine, USA – Phage 3.0: Spotlighting the Viral Genosphere for Drug Discovery, Biotechnology, and Novel Biological Functions
Iddo Weiner from BiomX Inc., Israel – A phase 1b/2a randomized, double-blind, placebo-controlled study evaluating nebulized phage therapy in cystic fibrosis subjects with chronic Pseudomonas aeruginosa pulmonary infection
Anders S. Nilsson from Stockholm University, Sweden – Novel Computer Program for Modelling Bacteriophage Infection Kinetics
Rodrigo Ibarra Chavez from University of Copenhagen, Denmark – Phage-Inducible Chromosomal Islands Promote Genetic Variability by Blocking Phage Reproduction
Amanda Burkardt CEO of Phiogen – Creating Patient Ready Products in a Remedy Ready World
Adam Ostrowski from Cellexus, UK – Implementing GMP Manufacturing for Phage Therapy
Antoine Culot from Rime Bioinformatics, France – Enhancing Phage Therapy Safety: Reliable and Sensitive Phage Genome Annotation with RTOOLS2 High-throughput Pipeline
Alexander Sturm from Resistell AG, Switzerland – Developing a Rapid Phenotypic Assessment of Phage Susceptibility Using a Nanomotion Technology Platform
Tatjana Mijatovic from R.E.D. Laboratories, Belgium – Borrelia Phelix Phage Test: Use of Specific Borrelia Phages as a New Strategy for Improved Diagnostic Tests
Wanqi Huang from Helmholtz Centre Munich, Germany – Comparison of Several Preservation Methods for Long-term Storage of Morphologically Distinct Bacteriophages
Van Hung Vuong Le from University of Copenhagen, Denmark – Catch Me if You Conjugate! Plasmid Recovery from Complex Ecosystems Using Secreted Pilus Machinery as a Hook
Emanuelle Mamroud from Israel Institute for Biological Research, Israel – Phage Therapy Potentiates Second-line Antibiotic Treatment Against Pneumonic Plague
Brieuc Van Nieuwenhuyse from UC Louvain, Belgium – Bacteriophage-Antibiotic Combination Therapy against Extensively Drug-Resistant Pseudomonas aeruginosa Infection to Allow Liver Transplantation in a Toddler
Geetha Kumar from Amrita University, India – Formulation of Bacteriophage Cocktails against Multidrug-Resistant Clinical Pseudomonas Aeruginosa Isolates From South India: Implications in Phage Therapy
Peter Kotsoana Montso from North-West University, South Africa – Comparative Genomics and Proteomics Analysis of Novel Phages Infecting Multi-Drug Resistant Escherichia coli O177 Strain
João Duarte from University of Aveiro, Portugal – Bacteriophages to Treat Urinary Tract Infections: Preliminary Studies against Klebsiela pneumonia
Jacob Zulk from Baylor College of Medicine, USA – Bacteriophage Resistance is Associated with Reduced Bacterial Fitness in the Urinary Environment
Laia Fernandez Barat from University of Barcelona, Spain – Synergies Between Phage and Antibiotic Therapy on Endotracheal Tube Biofilm
View past events by Phage Therapy Congress